Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Hair-Raising Stem Cell Find: Overactive Follicles, Sparser Pates

Hair follicle stem cells (HFSCs) lacking the protein FOXC1 spend less time in quiescence, leading to markedly shorter resting periods between hair cycles, with consequences for HFSC niches, or bulges. The HFSCs can retain only one old bulge in their hair folli

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Hair follicle stem cells (HFSCs) lacking the protein FOXC1 spend less time in quiescence, leading to markedly shorter resting periods between hair cycles, with consequences for HFSC niches, or bulges. The HFSCs can retain only one old bulge in their hair follicles, while normal stem cells can keep up to four. Ultimately, diminished HFSC niches result in premature graying and sparser coats. [The Laboratory of Mammalian Cell Biology and Development at Rockefeller University/PNAS]

Many adult stem cells seem to pace themselves as though they need to conserve their regenerative powers for the long haul. But whether these stem cells really need to alternate between periods of busyness and rest, or quiescence, remains an unsettled question.

To shed light on the question, scientists at Rockefeller University effectively took the brakes off stem cells of a particular kind, hair follicle stem cells (HFSCs). Alas, experiments in mice showed that supercharged stem cells did not give rise to richer, fuller coats of hair. Instead, coats grew grayer prematurely. Even worse, the coats became sparser.

These results appeared February 24 in the Proceedings of the National Academy of Sciences (PNAS), in an article entitled, “FOXC1 Maintains the Hair Follicle Stem Cell Niche and Governs Stem Cell Quiescence to Preserve Long-Term Tissue-Regenerating Potential.” FOXC1 refers to Forkhead box C1, a transcription factor expressed in HFSCs. These cells reside a niche called the bulge.

FOXC1-deficient mice were created by knocking out, or “conditionally ablating,” the gene that produces this protein. This intervention revealed that FOXC1 is involved not only in HFSC activity, but also bulge maintenance.

“FOXC1-deficient HFSCs spend less time in quiescence, leading to markedly shortened resting periods between hair cycles,” wrote the authors of the PNAS article. “The enhanced hair cycling accelerates HFSC expenditure, and impacts hair regeneration in aging mice. Interestingly, although FOXC1-deficient HFs can still form a new bulge that houses HFSCs for the next hair cycle, the older bulge is left unanchored. As the new hair emerges, the entire old bulge, including its reserve HFSCs and SC-inhibitory inner cell layer, is lost.”

Essentially, the knockout stem cells enter an overactive state in which they cannot establish quiescence adequately. Also, in the absence of FOXC1, hair follicles always had only one hair despite having made new hairs seven times. This is because these hair follicles could not retain their old bulges, though they generated a new bulge without a problem.

The Rockefeller University researchers attributed these changes to a two-part mechanism—first, a marked increase in cell cycle-associated transcripts upon FOXC1 ablation, and second, a downstream reduction in E-cadherin–mediated inter-SC adhesion.

“As the stem cells started proliferating more, they became less able to stick together,” the authors continued. “As a result, their old bulges did not stay properly tethered to the hair follicle when the newly growing hair pushed past it. And since the bulge emits quiescence signals, its loss activated the remaining stem cells even faster.”

While the hair follicle stem cells of FOXC1-deficient mice produce hairs at a relatively breakneck pace, this profligate growth seems to wear them out. Older knockout mice had sparser, greyer coats, and they could not regenerate their fur as quickly as their normal age-matched or younger peers. A similar phenomenon has been described in mouse hematopoietic stem cells, which give rise to blood cells; those stem cells that are more active in young animals appear to become exhausted as the animals grow older.

“Hair follicle stem cells influence the behavior of melanocyte stem cells, which co-inhabit the bulge niche,” explained Elaine Fuchs, Ph.D., the senior author of the PNAS study. “Thus, when the numbers of hair follicle stem cells declined with age, so too did the numbers of melanocyte stem cells, resulting in premature greying of whatever hairs were left.”

Not much is known about naturally occurring hair loss with age, but these balding knockout mice may provide a model to study it. Also, the mice may reveal mechanisms of more general interest.

“We thought initially that the key to hair growth might be the fountain of youth,” noted Dr. Fuchs. “But the mice's hair coat surprisingly thinned and greyed precociously.”

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01How stable is the antibody?

A crucial question often addressed during preclinical development focuses on the in vivo stability of therapeutic antibodies. Increasing the half-life of a therapeutic antibody has several benefits ranging from higher treatment efficacy to increased advantages for the patients who will have a fewer number of therapy sessions and a reduced cost. Given these compelling benefits, following the identification of therapeutic antibodies with the desired specificity, developers usually subject them to a refinement step to increase their stability. This process is often hindered by the lack of reliable experimental tools to predict the half-life of antibodies in patients. The major hurdle of using mouse models to predict antibody stability in the serum lies in the way immunoglobulin proteins are processed by the organism. In mammals, most proteins circulating in the serum undergo constant uptake by endothelial cells and are routed through the endosomes to the lysosomal compartment for degradation. In the endosomes, immunoglobulin G (IgG) proteins are recognized and bound by a transmembrane protein, called the neonatal Fc receptor (FcRn), which mediates their recycling to the plasma membrane and subsequent release back into the serum. As a result, the half-life of IgGs are significantly extended by this mechanism. Since most therapeutic antibodies belong to the IgG class, this recycling system is very relevant for their relative stability in the body. Remarkably, the relative affinity between IgGs and FcRn is extremely disparate between different species, with the mouse receptor showing a much higher affinity than its human counterpart.

Source: www.genengnews.com ↗
02Undruggable or unscreenable?

Another obstacle to discovering new PPI inhibitors is the lack of libraries designed to hunt for them, points out Philippe Roche, PhD, senior scientist at the Integrative Structural and Chemical Biology team at the Cancer Research Center of Marseilles, France. “If you screen PPIs using libraries that were designed for kinases or GPCRs, that’s why you don’t get a lot of good results,” he says. To that end, his group began assembling a library focused on orthosteric inhibitors of PPIs. The result was 2P2Idb, a hand-curated, structural database cataloguing orthosteric inhibitors of PPIs for which the interface had been 3D characterized. From analyzing these known PPI inhibitors, and what structures they had in common, Roche and his colleagues developed a model to predict whether compounds would likely inhibit PPIs. Using this method, 2P2Idb creates an enriched screening library that dramatically increases the hit rate compared to standard libraries. Having proven their success with a small library of 1600 compounds, they are in the process of expanding the library to 10,000 compounds. Once that’s published, “the idea is to make this library available to labs around the world,” Roche says. “We will provide the library free of charge for people to be able to screen PPI targets.”

Source: www.genengnews.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →